Isomorphic Labs wants to be behind every blockbuster.
What’s happening: The UK-based Google DeepMind spinout raised $2.1B in Series B funding to scale its AI drug discovery platform and advance proprietary therapeutics.
Moonshot. Built on AlphaFold breakthroughs, the company uses AI to model biology and predict molecular interactions, helping researchers design new drugs for cancer, immune disorders, and other complex diseases.
End game. Founder and Nobel Prize winner Demis Hassabis said “the No.1 application of AI should be to improve human health,” describing Isomorphic’s long-term mission as using AI to “solve all disease.”
Battleground. As pharma, biotech, and AI converge, Isomorphic landed one of the industry’s biggest funding rounds before ever revealing a lead drug candidate.
Fueling an arms race, companies like Eli Lilly, Novo Nordisk, OpenAI, and Anthropic are competing to build models, infrastructure, and AI-powered platforms for the future of medicine.
Looking ahead: Moving beyond chatbots, AI companies are targeting healthcare, therapeutics, and longevity as the industry’s next frontier.
